RxDoctor Payments Data

Jean Wallner

Physician Assistant · Tampa, FLNPI 1639220973

Payments from drug & device makers

$12,129in general payments, 2019–2025

Across 338 payments — averaging $35.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$4K
  • Amgen$2K
  • Novartis$876
  • Boehringer Ingelheim$620
  • Esperion Therapeutics, Inc.$545
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$516
  • plus $3K from 22 others

What the payments were for

  • Consulting fees$2,42320%
  • Travel & lodging$8547%
  • Food & beverage$8,80273%
  • Education$500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,129 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$22,386
Medicare patients
114
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab85$90,409
EliquisApixaban59$59,625
EntrestoSacubitril/Valsartan24$32,861
Praluent PenAlirocumab33$24,664
OzempicSemaglutide11$10,271
Rosuvastatin Calcium113$1,627
Ezetimibe123$1,524
Atorvastatin Calcium130$1,325
Metoprolol Succinate119$1,192
Valsartan28$836
ClopidogrelClopidogrel Bisulfate48$817
Amlodipine Besylate75$625
Losartan Potassium47$522
Dilt-XrDiltiazem Hcl11$414
Carvedilol54$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$342$59,62559 claims
NovartisEntresto$876$32,86124 claims
Novo NordiskOzempic$276$10,27111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →